Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ImmunoGen, Inc.IMGN · Entity 94428 | SVP & CHIEF MEDICAL OFFICER | June 30, 2023 | July 05, 2023 |
| Surrozen, Inc./DESRZN · Entity 6092 | Director | May 13, 2026 | May 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ImmunoGen, Inc.
Report date June 30, 2023 · Filed July 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 113,935 |
Reported balance
After 2023-06-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-06-30 · Grant · Acquired 3,264 · Balance 113,935 F1: These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan (the ESPP). It pertains to the ESPP purchase period from January 1, 2023 through June 30, 2023. F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 3, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan (the ESPP). It pertains to the ESPP purchase period from January 1, 2023 through June 30, 2023.
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 3, 2023.
Surrozen, Inc./DE
Report date May 13, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.14 · Expires 2036-05-12 | Direct | 5,550 |
Reported balance
After 2026-05-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-13 · Grant · Acquired 5,550 · Balance 5,550 F1: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2026 Filed May 14, 2026 20:22 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantDirector Stock Option (right to buy) · Derivative | 5,550 | $0.00 Strike: $30.14 | $0.00 |
DisclosureSEC source: 0001193125-26-224117 · ownership.xml · derivative · entry 1 Berkenblit Anna · CIK 0001691868 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,550 Underlying: Common Stock · 5,550 shares Expires 2036-05-12 F1 · derivative.exercise_date: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director. Read SEC document |
| May 14, 2025 Filed May 15, 2025 21:07 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantOption (right to buy) · Derivative | 1,333 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001593968-25-000607 · primary_01.xml · derivative · entry 1 Berkenblit Anna · CIK 0001691868 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,333 Underlying: Common Stock · 1,333 shares Expires 2035-05-14 F1 · derivative.exercise_date: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 00:14 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantOption (right to buy) · Derivative | 1,333 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001593968-24-000826 · primary_01.xml · derivative · entry 1 Berkenblit Anna · CIK 0001691868 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,333 Underlying: Common Stock · 1,333 shares Expires 2034-06-05 F1 · derivative.exercise_date: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 17:56 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantCommon Stock | 3,264 | $4.05 | $13,219.20 |
DisclosureSEC source: 0001415889-23-010828 · form4-07052023_090723.xml · nonDerivative · entry 1 Berkenblit Anna · CIK 0001691868 · SVP & CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,935 F1 · security: These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan (the ESPP). It pertains to the ESPP purchase period from January 1, 2023 through June 30, 2023. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 3, 2023. Read SEC document |
| May 18, 2023 Filed May 22, 2023 13:34 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantOption (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0000950170-23-023326 · ownership.xml · derivative · entry 1 Berkenblit Anna · CIK 0001691868 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-05-18 F1 · security: The options fully vest and become exercisable on the one-year anniversary of the grant date, subject to the reporting person's continuous service as a director. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 17:22 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantRestricted Stock Unit · Derivative | 63,400 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002106 · form4-02072023_100207.xml · derivative · entry 3 Berkenblit Anna · CIK 0001691868 · SVP & CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,400 Underlying: Common Stock · 63,400 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs shall vest with respect to 40% of such RSUs on the one-year anniversary of the date of grant and with respect to the remaining 60% of such RSUs on the eighteen-month anniversary of the date of grant, subject to continued service through each vesting date. F4 · derivative.expiration_date: The RSUs shall vest with respect to 40% of such RSUs on the one-year anniversary of the date of grant and with respect to the remaining 60% of such RSUs on the eighteen-month anniversary of the date of grant, subject to continued service through each vesting date. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 17:22 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantStock Option (right to buy) · Derivative | 256,300 | $0.00 Strike: $4.66 | $0.00 |
DisclosureSEC source: 0001415889-23-002106 · form4-02072023_100207.xml · derivative · entry 2 Berkenblit Anna · CIK 0001691868 · SVP & CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,300 Underlying: Common Stock · 256,300 shares Expires 2033-02-03 F3 · derivative.exercise_date: These options vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 17:22 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantRestricted Stock Unit · Derivative | 42,700 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002106 · form4-02072023_100207.xml · derivative · entry 1 Berkenblit Anna · CIK 0001691868 · SVP & CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,700 Underlying: Common Stock · 42,700 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date. F2 · derivative.expiration_date: The RSUs vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date. Read SEC document |
| December 30, 2022 Filed Jan 3, 2023 17:21 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantCommon Stock | 436 | $3.92 | $1,709.12 |
DisclosureSEC source: 0001415889-23-000108 · form4-01032023_100110.xml · nonDerivative · entry 1 Berkenblit Anna · CIK 0001691868 · SVP & CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,671 F1 · security: These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan (the ESPP). It pertains to the ESPP purchase period from July 1, 2022 through December 31, 2022 F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 1, 2022 Read SEC document |
| November 14, 2022 Filed Dec 27, 2022 17:13 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantStock Option (Right to Buy) · Derivative | 222,300 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001415889-22-012990 · form4-12272022_101256.xml · derivative · entry 2 Berkenblit Anna · CIK 0001691868 · SVP & CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,450 Underlying: Common Stock · 222,300 shares Expires 2030-02-07 F2 · derivative.exercise_date: On February 7, 2020, the reporting person was granted an option to purchase 444,600 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On November 14, 2022, certain performance criteria were met, resulting in the vesting of 50% of the performance stock option award. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 16:31 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantCommon Stock | 3,073 | $3.83 | $11,754.23 |
DisclosureSEC source: 0001415889-22-007332 · form4-07052022_010708.xml · nonDerivative · entry 1 Berkenblit Anna · CIK 0001691868 · SVP & CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,235 F1 · security: These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan (the ESPP). It pertains to the ESPP purchase period from January 1, 2022 through June 30, 2022 F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2022 Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:48 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantOption (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001593968-22-001108 · primary_01.xml · derivative · entry 1 Berkenblit Anna · CIK 0001691868 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Surrozen, Inc. Common Stock · 20,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: The options fully vest and become exercisable on the one-year anniversary of the grant date, subject to the reporting person's continuous service as a director. Read SEC document |
| May 20, 2022 Filed Dec 27, 2022 17:13 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantStock Option (Right to Buy) · Derivative | 111,150 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001415889-22-012990 · form4-12272022_101256.xml · derivative · entry 1 Berkenblit Anna · CIK 0001691868 · SVP & CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,150 Underlying: Common Stock · 111,150 shares Expires 2030-02-07 F1 · derivative.exercise_date: On February 7, 2020, the reporting person was granted an option to purchase 444,600 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On May 20, 2022, certain performance criteria were met, resulting in the vesting of 25% of the performance stock option award. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 17:31 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantStock Option (right to buy) · Derivative | 311,700 | $5.32 Strike: $5.32 | $1,658,244.00 |
DisclosureSEC source: 0001179110-22-000927 · edgar.xml · derivative · entry 1 Berkenblit Anna · CIK 0001691868 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,700 Underlying: Common Stock · 311,700 shares Expires 2032-02-04 F1 · derivative.exercise_date: These options vest over a four-year period, with 25% of the shares vesting on the one year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 16:08 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantCommon Stock | 1,761 | $5.60 | $9,861.60 |
DisclosureSEC source: 0001179110-22-000106 · edgar.xml · nonDerivative · entry 1 Berkenblit Anna · CIK 0001691868 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,162 F1 · security: These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan (the ESPP). It pertains to the ESPP purchase period from July 1, 2021 through December 31, 2021. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 1, 2021. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 16:22 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantCommon Stock | 2,062 | $5.52 | $11,382.24 |
DisclosureSEC source: 0001179110-21-007318 · edgar.xml · nonDerivative · entry 1 Berkenblit Anna · CIK 0001691868 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,401 F1 · security: These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan (the ESPP). It pertains to the ESPP purchase period from January 1, 2021 through June 30, 2021. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 4, 2021. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 20:09 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantCommon Stock (right to buy) · Derivative | 282,019 | $7.69 Strike: $7.69 | $2,168,726.11 |
DisclosureSEC source: 0001179110-21-001492 · edgar.xml · derivative · entry 1 Berkenblit Anna · CIK 0001691868 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,019 Underlying: Common Stock · 282,019 shares Expires 2031-02-05 F1 · derivative.exercise_date: These options vest over a four-year period, with 25% of the shares vesting on the one year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 08:58 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantCommon Stock | 2,203 | $4.04 | $8,900.12 |
DisclosureSEC source: 0001179110-21-000081 · edgar.xml · nonDerivative · entry 1 Berkenblit Anna · CIK 0001691868 · VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,339 F1 · security: These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from July 1, 2020 through December 31, 2020. F2 · price: In accordance with the ESPP; these shares were purchased based on 85% of the closing price of the issuer's common stock on July 1, 2020. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 08:39 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantCommon Stock | 3,047 | $3.91 | $11,913.77 |
DisclosureSEC source: 0001179110-20-007818 · edgar.xml · nonDerivative · entry 1 Berkenblit Anna · CIK 0001691868 · VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,136 F1 · security: These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from January 1, 2020 through June 30, 2020. F2 · price: In accordance with the ESPP; these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2020. Read SEC document |
| February 24, 2020 Filed Feb 25, 2020 08:37 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | SaleCommon Stock | 25,803 | $4.99 | $128,756.97 |
DisclosureSEC source: 0001179110-20-002185 · edgar.xml · nonDerivative · entry 1 Berkenblit Anna · CIK 0001691868 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,089 F2 · shares: The transaction reported in this Form 4 was made in connection with the satisfaction of the reporting person's tax withholding obligation arising from the vesting of restricted shares and was effected pursuant to a 10b5-1 trading plan executed by the reporting person. F1 · price: Weighted average price of shares sold. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 09:25 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantStock Option (right to buy) · Derivative | 296,400 | $4.55 Strike: $4.55 | $1,348,620.00 |
DisclosureSEC source: 0001179110-20-001426 · edgar.xml · derivative · entry 1 Berkenblit Anna · CIK 0001691868 · SVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,400 Underlying: Common Stock · 296,400 shares Expires 2030-02-07 F1 · derivative.exercise_date: 25% of the options are exercisable on the first year anniversary of the grant and the balance is exercisable in twelve equal installments of 6.25%, quarterly over the following three years starting one quarter after the first year anniversary. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 13:40 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantCommon Stock | 5,230 | $1.84 | $9,623.20 |
DisclosureSEC source: 0001179110-19-008317 · edgar.xml · nonDerivative · entry 1 Berkenblit Anna · CIK 0001691868 · VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,892 F1 · security: These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from January 1, 2019 through June 30, 2019. F2 · price: In accordance with the ESPP; these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2019. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 16:36 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantStock Option (right to buy) · Derivative | 92,500 | $5.25 Strike: $5.25 | $485,625.00 |
DisclosureSEC source: 0001179110-19-001230 · edgar.xml · derivative · entry 2 Berkenblit Anna · CIK 0001691868 · VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,500 Underlying: Common Stock · 92,500 shares Expires 2029-01-31 F2 · derivative.exercise_date: Exercisable in four equal installments over the next four years starting on the first year anniversary of the grant. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 16:36 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantStock Option (right to buy) · Derivative | 256,050 | $5.25 Strike: $5.25 | $1,344,262.50 |
DisclosureSEC source: 0001179110-19-001230 · edgar.xml · derivative · entry 1 Berkenblit Anna · CIK 0001691868 · VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,050 Underlying: Common Stock · 256,050 shares Expires 2029-01-31 F1 · derivative.exercise_date: Exercisable in three equal installments over the next three years starting on the first year anniversary of the grant. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 11:07 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantCommon Stock | 2,455 | $4.08 | $10,016.40 |
DisclosureSEC source: 0001179110-19-000356 · edgar.xml · nonDerivative · entry 1 Berkenblit Anna · CIK 0001691868 · VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,224 F1 · security: These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from July 1, 2018 through December 31, 2018. F2 · price: In accordance with the ESPP; these shares were purchased based on 85% of the closing price of the issuer's common stock on December 31, 2018. Read SEC document |
| October 16, 2018 Filed Oct 17, 2018 09:51 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | SaleCommon Stock | 5,851 | $8.00 | $46,808.00 |
DisclosureSEC source: 0001179110-18-012212 · edgar.xml · nonDerivative · entry 1 Berkenblit Anna · CIK 0001691868 · VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,769 F2 · shares: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan executed by the reporting person. F1 · price: Weighted average price of shares sold. Read SEC document |
| September 10, 2018 Filed Sep 11, 2018 17:20 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | SaleCommon Stock | 5,851 | $9.46 | $55,350.46 |
DisclosureSEC source: 0001179110-18-011292 · edgar.xml · nonDerivative · entry 1 Berkenblit Anna · CIK 0001691868 · VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,620 F2 · shares: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan executed by the reporting person. F1 · price: Weighted average price of shares sold. Read SEC document |
| February 22, 2018 Filed Feb 25, 2019 10:10 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | SaleCommon Stock | 16,562 | $5.60 | $92,747.20 |
DisclosureSEC source: 0001179110-19-002468 · edgar.xml · nonDerivative · entry 1 Berkenblit Anna · CIK 0001691868 · VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,662 F2 · shares: The transaction reported in this Form 4 was made in connection with the satisfaction of the reporting person's tax withholding obligation arising from the vesting of restricted shares and was effected pursuant to a 10b5-1 trading plan executed by the reporting person. F1 · price: Weighted average price of shares sold. Read SEC document |
| February 21, 2018 Filed Feb 23, 2018 11:45 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | SaleCommon Stock | 17,329 | $10.88 | $188,539.52 |
DisclosureSEC source: 0001179110-18-002672 · edgar.xml · nonDerivative · entry 1 Berkenblit Anna · CIK 0001691868 · VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,471 F2 · shares: The transaction reported in this Form 4 was made in connection with the satisfaction of the reporting person's tax withholding obligation arising from the vesting of restricted shares and was effected pursuant to a 10b5-1 trading plan executed by the reporting person. F1 · price: Weighted average price of shares sold. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 16:02 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantStock Option (right to buy) · Derivative | 175,000 | $10.65 Strike: $10.65 | $1,863,750.00 |
DisclosureSEC source: 0001179110-18-002365 · edgar.xml · derivative · entry 1 Berkenblit Anna · CIK 0001691868 · VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2028-02-15 F1 · derivative.exercise_date: Exercisable in three equal installments over the next three years starting on the first year anniversary of the grant. Read SEC document |
| September 13, 2017 Filed Sep 18, 2017 11:16 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | SaleCommon Stock | 1,500 | $7.00 | $10,500.00 |
DisclosureSEC source: 0001179110-17-012351 · edgar.xml · nonDerivative · entry 1 Berkenblit Anna · CIK 0001691868 · VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,800 Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 15:21 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantCommon Stock | 157,300 | $2.47 | $388,531.00 |
DisclosureSEC source: 0001179110-17-003019 · edgar.xml · nonDerivative · entry 1 Berkenblit Anna · CIK 0001691868 · VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,300 F1 · shares: These shares are restricted stock which vest annually in three equal installments commencing on February 21, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.